Achyut Healthcare Ltd
Incorporated in 1996, Achyut Healthcare Ltd is a pharmaceutical trading company dealing in API, Pharmaceutical products, medical devices, etc.[1]
- Market Cap ₹ 139 Cr.
- Current Price ₹ 5.77
- High / Low ₹ 6.80 / 3.18
- Stock P/E 435
- Book Value ₹ 1.45
- Dividend Yield 0.00 %
- ROCE 1.23 %
- ROE 0.96 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Debtor days have improved from 76.8 to 45.7 days.
- Company's working capital requirements have reduced from 834 days to 91.0 days
Cons
- Stock is trading at 3.97 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 1.58% over last 3 years.
- Promoter holding has decreased over last 3 years: -6.37%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 0.67 | 0.33 | 0.27 | 4.05 | 2.70 | 6.14 | 3.05 | 11.59 | |
| 0.66 | 0.32 | 0.26 | 4.08 | 2.97 | 6.12 | 3.25 | 11.42 | |
| Operating Profit | 0.01 | 0.01 | 0.01 | -0.03 | -0.27 | 0.02 | -0.20 | 0.17 |
| OPM % | 1.49% | 3.03% | 3.70% | -0.74% | -10.00% | 0.33% | -6.56% | 1.47% |
| 0.00 | 0.01 | 0.00 | 0.14 | 0.59 | 0.73 | 0.92 | 0.38 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.14 |
| Profit before tax | 0.01 | 0.02 | 0.01 | 0.10 | 0.31 | 0.74 | 0.70 | 0.37 |
| Tax % | 300.00% | 0.00% | 0.00% | 60.00% | 25.81% | 32.43% | 22.86% | 16.22% |
| -0.01 | 0.01 | 0.01 | 0.04 | 0.23 | 0.50 | 0.55 | 0.32 | |
| EPS in Rs | -0.02 | 0.02 | 0.02 | 0.00 | 0.01 | 0.02 | 0.02 | 0.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 112% |
| 3 Years: | 63% |
| TTM: | 280% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 100% |
| 3 Years: | 12% |
| TTM: | -42% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 19% |
| 1 Year: | 73% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 0.25 | 6.74 | 9.35 | 16.83 | 23.56 | 24.14 |
| Reserves | -0.05 | -0.04 | 0.00 | 2.34 | 5.18 | 13.93 | 7.74 | 10.93 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | |
| 0.04 | 0.06 | 0.25 | 0.86 | 0.81 | 0.19 | 1.29 | 2.84 | |
| Total Liabilities | 0.24 | 0.27 | 0.50 | 9.94 | 15.34 | 30.95 | 32.59 | 38.09 |
| 0.00 | 0.00 | 0.00 | 0.03 | 0.05 | 0.06 | 0.03 | 1.55 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 3.49 | 9.16 | 18.19 | 27.88 |
| Investments | 0.00 | 0.00 | 0.00 | 1.70 | 1.30 | 0.00 | 0.00 | 0.00 |
| 0.24 | 0.27 | 0.50 | 8.21 | 10.50 | 21.73 | 14.37 | 8.66 | |
| Total Assets | 0.24 | 0.27 | 0.50 | 9.94 | 15.34 | 30.95 | 32.59 | 38.09 |
Cash Flows
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| -0.03 | -0.02 | 0.01 | -6.96 | -0.43 | -0.36 | -4.06 | ||
| 0.00 | 0.00 | 0.00 | -1.60 | -4.81 | -15.23 | 4.69 | ||
| 0.00 | 0.00 | 0.00 | 8.79 | 5.21 | 15.72 | 0.00 | ||
| Net Cash Flow | -0.03 | -0.02 | 0.01 | 0.24 | -0.03 | 0.14 | 0.62 | |
| Free Cash Flow | -0.03 | -0.02 | 0.01 | -6.99 | -3.75 | -6.37 | -14.92 | |
| CFO/OP | -300% | -100% | 100% | 23,100% | 126% | -700% | 1,945% |
Ratios
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54.48 | 188.03 | 378.52 | 18.02 | 36.50 | 24.37 | 160.36 | 45.66 |
| Inventory Days | 0.00 | 0.00 | 158.70 | 14.29 | 59.59 | 3.96 | 24.16 | 15.79 |
| Days Payable | 380.87 | 41.78 | 55.87 | 12.54 | 143.71 | 44.43 | ||
| Cash Conversion Cycle | 54.48 | 188.03 | 156.34 | -9.46 | 40.22 | 15.79 | 40.81 | 17.02 |
| Working Capital Days | 76.27 | 210.15 | 216.30 | 603.83 | 1,257.22 | 1,242.43 | 1,169.20 | 91.01 |
| ROCE % | 9.76% | 4.35% | 2.14% | 2.63% | 3.27% | 2.26% | 1.23% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Capital Work In Progress (CWIP) INR Lakhs |
|
||||
| Domestic Sales INR Lakhs |
|||||
| Export Sales INR Lakhs |
|||||
| Manufacturing Status Status |
|||||
| Number of Permanent Employees Count |
|||||
| Trade Receivable Turnover Ratio Ratio |
|||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Paper Cutting of Published Audited Financial Result for the Quarter and Year ended 31st March, 2026
-
Submission Of Statement Of Deviation Or Variation For Proceeds Of Public Issue Pursuant To Regulation 32 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015 For The Year Ended On 31St March, 2026
2d - Filed Regulation 32 statement for half year ended 31 March 2026; no deviation in public issue proceeds.
-
Outcome Of Board Meeting General Update
2d - Board approved FY26 audited results on 27 May 2026; net profit Rs 31.57 lakh, AGM dates to follow.
-
Appointment Of Internal Auditor For The Financial Year 2026-27 Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015.
2d - Board appointed M/s. Mohta Khetawat & Co. as Internal Auditor for FY 2026-27.
- Standalone Audited Financial Result For The Quarter Yearly & Year Ended On 31.03.2026 2d
Business Overview:[1]
Company is in the manufacturing of
pharmaceutical formulations in the
forms of Tablets, Capsules, Oral liquid
and Injectables.